Cargando…

Combination antiretroviral therapy improves recurrent primary biliary cholangitis following liver transplantation

Recurrent primary biliary cholangitis (rPBC) is frequent following liver transplantation and associated with increased morbidity and mortality. It has been argued that rPBC behaves like an infectious disease because more potent immunosuppression with tacrolimus is associated with earlier and more se...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lytvyak, Ellina, Niazi, Mina, Pai, Rohit, He, Daniel, Zhang, Guangzhi, Hübscher, Stefan G., Mason, Andrew L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Gut‐liver Axis, Immunology, Immune Mediated and Cholestatic Diseases
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8362166/ https://www.ncbi.nlm.nih.gov/pubmed/34008271 http://dx.doi.org/10.1111/liv.14964

Ejemplares similares

Portal pressure is of significant prognostic value in primary biliary cholangitis
por: Warnes, Thomas W., et al.
Publicado: (2022)

Reduction and stabilization of bilirubin with obeticholic acid treatment in patients with primary biliary cholangitis
por: Parés, Albert, et al.
Publicado: (2020)

Impact on follow‐up strategies in patients with primary sclerosing cholangitis
por: Bergquist, Annika, et al.
Publicado: (2022)

High prevalence of lower limb atherosclerosis is linked with the gut–liver axis in patients with primary biliary cholangitis
por: Ponziani, Francesca Romana, et al.
Publicado: (2022)

Predictors of serious adverse events and non‐response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid
por: De Vincentis, Antonio, et al.
Publicado: (2022)

A novel serum metabolomic panel distinguishes IgG4‐related sclerosing cholangitis from primary sclerosing cholangitis
por: Radford‐Smith, Daniel E., et al.
Publicado: (2022)

The Simple Cholestatic Complaints Score is a valid and quick patient‐reported outcome measure in primary sclerosing cholangitis
por: van Munster, Kim N., et al.
Publicado: (2020)

A novel non‐bile acid FXR agonist EDP‐305 potently suppresses liver injury and fibrosis without worsening of ductular reaction
por: An, Ping, et al.
Publicado: (2020)

High discontinuation rate of azathioprine in autoimmune hepatitis, independent of time of treatment initiation
por: Pape, Simon, et al.
Publicado: (2020)

Disease severity and proton pump inhibitor use impact strongest on faecal microbiome composition in liver cirrhosis
por: Stadlbauer, Vanessa, et al.
Publicado: (2020)

Environmental risk factors are associated with autoimmune hepatitis
por: Lammert, Craig, et al.
Publicado: (2021)

Symptom patterns in the daily life of PSC patients
por: van Munster, Kim N., et al.
Publicado: (2022)

Extrahepatic autoimmune diseases in autoimmune hepatitis: Effect on mortality
por: Birn‐Rydder, Rasmine, et al.
Publicado: (2022)

Confidence in treatment is contributing to quality of life in autoimmune liver diseases. The results of ERN RARE‐LIVER online survey
por: Wunsch, Ewa, et al.
Publicado: (2022)

A shared mucosal gut microbiota signature in primary sclerosing cholangitis before and after liver transplantation
por: Hole, Mikal Jacob, et al.
Publicado: (2023)

Widespread gaps in the quality of care for primary biliary cholangitis in UK
por: Sivakumar, Mathuri, et al.
Publicado: (2021)

Bile acids increase steroidogenesis in cholemic mice and induce cortisol secretion in adrenocortical H295R cells via S1PR2, ERK and SF‐1
por: Liu, Lei, et al.
Publicado: (2019)

Immunoglobulin G4(+) B‐cell receptor clones distinguish immunoglobulin G 4‐related disease from primary sclerosing cholangitis and biliary/pancreatic malignancies
por: Doorenspleet, Marieke E., et al.
Publicado: (2016)

Compartment-specific immunity in the human gut: properties and functions of dendritic cells in the colon versus the ileum
por: Mann, Elizabeth R, et al.
Publicado: (2016)

Serum Immunoglobulin G4 and Immunoglobulin G1 for Distinguishing Immunoglobulin G4-Associated Cholangitis From Primary Sclerosing Cholangitis
por: Boonstra, Kirsten, et al.
Publicado: (2014)

Secondary sclerosing cholangitis following COVID-19 disease: a multicenter retrospective study
por: Hunyady, Peter, et al.
Publicado: (2022)

Impact of combination antiretroviral therapy in the NOD.c3c4 mouse model of autoimmune biliary disease
por: Sharon, David, et al.
Publicado: (2015)

Vitamin D Is Associated with Clinical Outcomes in Patients with Primary Biliary Cholangitis
por: Ebadi, Maryam, et al.
Publicado: (2022)

Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study
por: Hirschfield, Gideon M., et al.
Publicado: (2023)

Utility of fluorescence imitating brightfield imaging microscopy for the diagnosis of feline chronic enteropathy
por: Au Yeung, Sarah, et al.
Publicado: (2022)

Electrostatic Modifications of the Human Leukocyte Antigen-DR P9 Peptide-Binding Pocket and Susceptibility to Primary Sclerosing Cholangitis
por: Hov, Johannes R, et al.
Publicado: (2011)

Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2‐deficient mice
por: Zhou, Mei, et al.
Publicado: (2016)

Liver Transplantation for Recurrent Cholangitis From Von Meyenburg Complexes
por: Panda, Nikhil, et al.
Publicado: (2019)

The renin‐angiotensin‐aldosterone system, neurohumoral axis and cardiovascular mortality in LURIC
por: Yazdani, Babak, et al.
Publicado: (2022)

Increased expression of the urokinase plasminogen activator system by Helicobacter pylori in gastric epithelial cells
por: Kenny, Susan, et al.
Publicado: (2008)

EP(2) and EP(4) receptors on muscularis resident macrophages mediate LPS-induced intestinal dysmotility via iNOS upregulation through cAMP/ERK signals
por: Tajima, Tsuyoshi, et al.
Publicado: (2012)

Intestinal epithelial suppressor of cytokine signaling 3 enhances microbial-induced inflammatory tumor necrosis factor-α, contributing to epithelial barrier dysfunction
por: Thagia, Imtiyaz, et al.
Publicado: (2014)

Why Doesn’t Primary Biliary Cholangitis Respond to Immunosuppressive Medications?
por: Molinaro, Antonio, et al.
Publicado: (2017)

The SRL peptide of rhesus rotavirus VP4 protein governs cholangiocyte infection and the murine model of biliary atresia
por: Mohanty, Sujit K., et al.
Publicado: (2017)

Vitamin D Nuclear Receptor Deficiency Promotes Cholestatic Liver Injury by Disruption of Biliary Epithelial Cell Junctions in Mice
por: Firrincieli, Delphine, et al.
Publicado: (2013)

Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD
por: Sabino, João, et al.
Publicado: (2016)

IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH
por: Xu, Jun, et al.
Publicado: (2023)

Human intrahepatic regulatory T cells are functional, require IL‐2 from effector cells for survival, and are susceptible to Fas ligand‐mediated apoptosis
por: Chen, Yung‐Yi, et al.
Publicado: (2016)

Long-term Prognosis and Recurrence of Primary Sclerosing Cholangitis After Liver Transplantation: A Single-Center Experience
por: Ueda, Yoshihide, et al.
Publicado: (2017)

Effective treatment of canine chronic cutaneous lupus erythematosus variants with oclacitinib: Seven cases
por: Harvey, Richard G., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dhu4dj2bta97j7vv9t6374bpbo